A comparator trial of BPX-501 in malignant and nonmalignant pediatric patients receiving a matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT).

Trial Profile

A comparator trial of BPX-501 in malignant and nonmalignant pediatric patients receiving a matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT).

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2017

At a glance

  • Drugs Rivogenlecleucel (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2017 According to a Bellicum Pharmaceuticals media release, the company expects full enrolled later this year.
    • 14 Dec 2016 New trial record
    • 05 Dec 2016 According to a Bellicum Pharmaceuticals media release, this trial will include up to 40 prospective patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top